APOE and Alzheimer disease: Recently, computational evaluation of APOE genotype-dependent transcriptomics signatures of human AD brain combined with query of a drug database of transcriptomic signatures identified bumetanide as a top-scoring drug that reverses transcriptomic AD signatures of the APOE4 genotype (Taubes et al., 2021).